U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

CNS Active
3913
Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Smithson, R.
38
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Activator
1430
Activator
1430
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1430
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8429
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
Approved
8429
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
Approved
8429
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8429
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.
1991 Apr 1
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.
1991 Sep 10
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.
1997 May 16
Inhibition of HIV-1 infection by zinc group metal compounds.
1999 Sep
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.
2004 Jul 30
High-throughput computational and experimental techniques in structural genomics.
2004 Oct
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
[Reduced thymulin production during occupational exposure to lead].
2005 Jan-Mar
Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise.
2005 May
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.
2006 Apr
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
2007 May
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
2007 Nov
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.
2009 Mar 28
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
2010 Dec 1
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Molecular cloning, characterization of copper/zinc superoxide dismutase and expression analysis of stress-responsive genes from Eisenia fetida against dietary zinc oxide.
2012 Mar
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015 Apr 2
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.
2015 Jan 25
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
2015 Sep
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Name Type Language
GLUCARPIDASE
DASH   INN   VANDF   WHO-DD  
INN  
Official Name English
VORAXAZE
Brand Name English
PTEROYLMONOGLUTAMIC ACID HYDROLASE G2
Common Name English
glucarpidase [INN]
Common Name English
FOLATE HYDROLASE G2
Common Name English
CARBOXYPEPTIDASE G2
Common Name English
CPG2
Common Name English
Glucarpidase [WHO-DD]
Common Name English
GLUCARPIDASE [VANDF]
Common Name English
GLUCARPIDASE [MI]
Common Name English
GLUCARPIDASE [JAN]
Common Name English
.GAMMA.-GLU-X CARBOXYPEPTIDASE
Common Name English
GLUCARPIDASE [PURPLE BOOK CDER]
Common Name English
RECOMBINANT GLUTAMATE CARBOXYPEPTIDASE (CARBOXYPEPTIDASE G2)
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/02/128
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
WHO-VATC QV03AF09
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
NCI_THESAURUS C29726
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
NDF-RT N0000184013
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
WHO-ATC V03AF09
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
FDA ORPHAN DRUG 163702
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
Code System Code Type Description
DAILYMED
2GFP9BJD79
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
IUPHAR
7450
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
EVMPD
SUB25203
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
ChEMBL
CHEMBL1863515
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
RXCUI
1242127
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
5138
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
PUBCHEM
21195079
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
MERCK INDEX
m11689
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
ECHA (EC/EINECS)
232-978-1
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
CAS
9074-87-7
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
DRUG BANK
DB08898
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
NCI_THESAURUS
C346
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
NDF-RT
N0000167577
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY Carboxypeptidases [Chemical/Ingredient]
FDA UNII
2GFP9BJD79
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
WIKIPEDIA
Glucarpidase
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
INN
8509
Created by admin on Sat Dec 16 01:41:01 GMT 2023 , Edited by admin on Sat Dec 16 01:41:01 GMT 2023
PRIMARY
ACTIVE MOIETY
GLUCARPIDASE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966